Skip to content

Jennifer Keller

3 papers in the library · 71 citations · publishing 2023-2026

Papers

Sort Most recent Most cited

Low-Dose Buprenorphine Following Ketamine Treatment for Suicidal Ideation in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.

The American journal of psychiatry June 1, 2026 Jason M Tucciarone, Igor D. Bandeira, Christine Blasey et al. 5 citations

Ketamine rapidly reduces suicidal ideation in major depressive disorder (MDD), but its effects are transient. Preclinical and clinical studies suggest that ketamine's antidepressant and antisuicidal effects may be partly mediated by mu-opioid receptor (MOR) modulation. The authors investigated the efficacy and safety of low-dose sublingual buprenorphine, a partial MOR agonist, as a follow-on...

Magnesium-ibogaine therapy in veterans with traumatic brain injuries.

Nature Medicine February 1, 2024 Kirsten Cherian, Jackob N. Keynan, Lauren Anker et al. 66 citations

Traumatic brain injury (TBI) is a leading cause of disability. Sequelae can include functional impairments and psychiatric syndromes such as post-traumatic stress disorder (PTSD), depression and anxiety. Special Operations Forces (SOF) veterans (SOVs) may be at an elevated risk for these complications, leading some to seek underexplored treatment alternatives such as the oneirogen ibogaine, a...

22 The Effect of Ibogaine on Cognitive Functioning

Journal of the International Neuropsychological Society November 1, 2023 Kirsten Cherian, Afik Faerman, Lauren Anker et al.

Objective: To determine the effects of the non-classic psychedelic, ibogaine, on cognitive functioning. Ibogaine is an indole alkaloid derived from the Tabernanthe Iboga plant family, indigenous to Africa, and traditionally used in spiritual and healing ceremonies. Ibogaine has primarily been studied with respect to its clinical efficacy in reducing substance addiction. There are, however,...